Literature DB >> 1838105

Comparative therapeutic efficacy of teicoplanin and vancomycin in normal and in neutropenic mice infected with Staphylococcus haemolyticus.

H L Torney1, F J Balistreri, M T Kenny, W D Cheng.   

Abstract

This study describes the evaluation of a murine bacteraemia model for assessing antibiotic efficacy in normal and neutropenic mice infected with coagulase-negative staphylococci. In one such evaluation, it was found that there was no significant (P greater than 0.05) difference in the ability of teicoplanin or vancomycin to protect normal or neutropenic CD-1 mice, lethally-infected with Staphylococcus haemolyticus. However, about a four-fold increase of either antibiotic was needed to protect the immunocompromised animals.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1838105     DOI: 10.1093/jac/28.2.261

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model.

Authors:  J D Knudsen; K Fuursted; F Espersen; N Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

2.  Population pharmacokinetic study of teicoplanin in severely neutropenic patients.

Authors:  O Lortholary; M Tod; N Rizzo; C Padoin; O Biard; P Casassus; L Guillevin; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 3.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

4.  Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection.

Authors:  J D Knudsen; K Fuursted; S Raber; F Espersen; N Frimodt-Moller
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.

Authors:  Federico Pea; Pierluigi Viale; Anna Candoni; Federica Pavan; Leonardo Pagani; Daniela Damiani; Marco Casini; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 6.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.